CIK 0001873835
- Emerging growth company
Immix Biopharma, Inc.
Sign in to watch- Ticker
- IMMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 454869378
- Phone
- +1 888-958-1084
- Business address
- 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, 90064
- Former names
- Immix Biopharma, Inc.
- 4 Open-market buy CEO and Chairman bought 3,300 shares at $1.81 ($5,970)
- 4 Grant or award Director acquired 161,981 shares (grant or award)
- 4 Grant or award CEO and Chairman acquired 218,359 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 2,459 shares (grant or award)
- 4 Grant or award Director acquired 46,157 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award CFO acquired 242,500 shares (grant or award)
- 4 Open-market buy CFO bought 4,500 shares at $2.23 ($10,042)
- 4 Open-market buy CEO and Chairman bought 4,300 shares at $2.25 ($9,660)
- 4 Open-market buy Director bought 56,000 shares at an average $4.77 ($266,919)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market buy Director bought 72,000 shares at an average $2.78 ($200,312)
- 4 Open-market buy Director bought 10,000 shares at $2.58 ($25,760)
- 4 Open-market buy Director bought 13,000 shares at $2.96 ($38,492)
- 4 Open-market buy Director bought 10,000 shares at $2.53 ($25,317)
- 4 Open-market buy Director bought 20,000 shares at $2.46 ($49,226)
- 4 Open-market buy Director bought 9,000 shares at $2.47 ($22,213)
- 4 Open-market buy Director bought 10,000 shares at $2.47 ($24,722)
Page 3 of 5 · 96 filings